Evidence map›Paper›PMID 36163637›Full record

Observational studyPediatrics international : official journal of the Japan Pediatric Society2022

Real-world etiologies and treatments of pediatric short bowel syndrome in Japan.

Yuko Tazuke, Eri Udagawa, Tsunekazu Mizushima, Shiro Nakamura, Jovelle Fernandez, Hiroomi Okuyama

Open access · hybridAbstract readObservational Study
In one paragraph

Observational study in Pediatrics international : official journal of the Japan Pediatric Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Yuko TazukeDepartment of Pediatric Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.
Eri UdagawaJapan Medical Office, Takeda Pharmaceutical Company Limited, Tokyo, Japan.
Tsunekazu MizushimaDepartment of Therapeutics for Inflammatory Bowel Diseases, Osaka University Graduate School of Medicine, Osaka, Japan.
Shiro Nakamura2nd Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Jovelle FernandezJapan Medical Office, Takeda Pharmaceutical Company Limited, Tokyo, Japan.
Hiroomi OkuyamaDepartment of Pediatric Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.ORCID https://orcid.org/0000-0002-1347-282X
The University of Osaka · JPTakeda (Japan) · JPOsaka University of Pharmaceutical Sciences · JP

Funding

Takeda Pharmaceutical Company Limited (Tokyo, Japan) N/A
6 · The paper itself

Abstract

backgroundShort bowel syndrome (SBS) is a rare disease that can result in intestinal failure (IF). Short bowel syndrome intestinal failure leads to stunted growth and development and high mortality rates. The primary goal of treatment is to enhance intestinal adaptation and nutrient absorption. Parenteral nutrition (PN) is used to support this process until enteral autonomy can be restored. Some patients experience prolonged partial or complete dependency on PN and face an increased risk of life-threatening catheter-related bloodstream infections and intestinal failure-associated liver disease. This study aimed to provide real-world insights into the patient characteristics and treatment dynamics of PN-dependent children with SBS-IF in Japan.

methodsThis retrospective observational study used anonymized information from a large hospital-based medical insurance database to identify pediatric patients who received PN for ≥6 months between April 2008 and January 2020. The primary endpoint was weaning from PN. Secondary endpoints included duration and complications of PN.

resultsForty-eight children (mean age, 2.9 years) were eligible for inclusion. The most common causes of SBS-IF were mechanical bowel obstruction, functional bowel disorders, and Hirschsprung's disease. Twenty-two patients (45.8%) were weaned from PN during the study. The mean time to first weaning was 464.2 days and five patients (22.7%) restarted PN. The mean total duration of PN was 692.6 days in weaned patients and 1,170.9 days in unweaned patients. The most frequent complications were sepsis, catheter infections (both 79.2%), and liver dysfunction (64.6%).

conclusionsPediatric patients with SBS-IF faced difficulties when weaning off PN and rates of life-threatening complications were high.

Indexed as

Intestinal DiseasesLiver DiseasesShort Bowel SyndromeChildChild, PreschoolHumansIntestine, SmallJapanParenteral NutritionRetrospective Studieschildetiologyparenteral nutritionshort bowel syndromeweaning

Identifiers

PMID36163637
PMCPMC9828786
OpenAlexW4289334746

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.